|Videos|January 18, 2023
Unmet Needs, Future Directions, and Clinical Pearls in mCRPC
Author(s)Stephen J. Freedland, MD
Dr. Freedland closes his discussion by highlighting remaining unmet needs in mCRPC treatment and providing some clinical pearls for community oncologists treating patients with the disease.
Advertisement
Episodes in this series
Advertisement
Related to this article
Moderators and participants reviewed ARANOTE, ARACOG, and ARASEC data and how they inform individualized treatment for mCSPC.
Jack R. Andrews, MD, discusses BED-PSMA-411 findings comparing PSMA-PET detection rates and urinary excretion in prostate cancer biochemical recurrence.
VIR-5500 is a PSMA-targeted PRO-XTEN dual-masked T-cell engager entering phase 3 development for prostate cancer.
Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.
Based on these results, the trial protocol has been amended to move enrollment earlier in the course of disease progression.
An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.
Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves nogapendekin alfa inbakicept plus BCG for papillary-only BCG-unresponsive NMIBC
2
Study compares PSMA-PET radiopharmaceuticals in prostate cancer recurrence
3
Matching mCSPC treatment to the patient, not just the trial data
4
Urocross Expander System enters US commercial use for symptomatic BPH
5